Every earnings call for AJANTPHARM — management tone, guidance, KPIs and promise tracking, quarter by quarter.
AJANTPHARM · 3 transcripts · Healthcare · latest Q4 FY26Ajanta Pharma Limited has 3 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue from Operations (FY26) ₹5,453 cr (+17% YoY); EBITDA (FY26) ₹1,395 cr (+11% YoY); EBITDA Margin (FY26) 26%. FY26 Revenue surpassed ₹5,000 crores, Net Profit crossed ₹1,000 crores.
Read full transcript & analysisRevenue ₹1,375 cr (+20% YoY); EBITDA ₹382 cr (+19% YoY); EBITDA Margin 28%. Total Revenue for Q3 stood at ₹1,375 crores, registering a healthy growth of 20% YoY.
Read full transcript & analysisRevenue from Operations ₹1,303 cr (+14% YoY); EBITDA Margin 27%; PAT ₹255 cr (+4% YoY). Revenue from operations grew by 14% to ₹1,303 crores.
Read full transcript & analysis